## UF BPA Appendix for the May 2015 DoD P&T Meeting

Uniform Formulary Price Quotes and Uniform Formulary Blanket Purchase Agreements (BPA)

The following Condition Sets, as authorized at each listed UF Drug Class Page, identify the conditions under which UF BPA price quotes are to be submitted by the Company.

Medications placed on the Uniform Formulary but not BCF or ECF are available for the local Military Treatment Facility P&T to decide whether to place on their individual formulary.

The Company must submit a separate, complete UF BPA price quote for each NDC (enter in table below\*) that applies to the Company's pharmaceutical agent(s) in a given drug class.

| NDC | Drug Name | Strength | Dosage Form | Package Size |  |
|-----|-----------|----------|-------------|--------------|--|
|     |           |          |             |              |  |

### DoD P&T Class: HEPATITIS C AGENTS Subclass: DIRECT ACTING AGENTS

Class Note(s): Grandfathering applies to this class/subclass.

Step Therapy Addendum: Step therapy, a prior authorization process, would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process. Step therapy applies to Hepatitis C Genotype 1 ONLY

|  |  | One of (X)                | Military Treatment Facility & Mail Order                                |  |  |
|--|--|---------------------------|---|--|--|
| Condition Set #                                    | Category **  | number of<br>brand agents | Price per Unit of<br>Measure (each, gram,<br>mL) to 4 decimal<br>places | Price Per<br>NDC to<br>4 decimal<br>places |  |
| Military Treatment Facility & Mail 153HCDIG1UFBS1X | Uniform Formulary but<br>not BCF or ECF Before<br>Step Therapy | 1                         | \$  | \$   |  |
|  |  |                           |   |  |  |
| Military Treatment Facility & Mail 153HCDIG1UFBS2X | Uniform Formulary but<br>not BCF or ECF Before<br>Step Therapy | 2                         | \$  | \$   |  |
|  |  |                           |   |  |  |
| Military Treatment Facility & Mail 153HCDIG0UFNS1M | Uniform Formulary but<br>not BCF or ECF No Step<br>Therapy     | 1 or more                 | \$  | \$   |  |
|  |  |                           |   |  |  |
| Military Treatment Facility & Mail 153HCDIG1UFAS1M | Uniform Formulary but<br>not BCF or ECF After<br>Step Therapy  | 1 or more                 | \$  | \$   |  |
|  |  |                           |   |  |  |

<sup>\*\*</sup> Only one price per category may be submitted.

## UF VARR Appendix for the May 2015 DoD P&T Meeting

#### Condition Sets for Uniform Formulary Voluntary Agreements for TRICARE Retail Refunds (UF-VARR)

The following Condition Sets, as authorized at each listed UF Drug Class Page, identify the conditions under which UF-VARR quotes are to be submitted by the Company.

The Company must submit a separate, complete UF-VARR quote for each Condition Set that applies to the Company's pharmaceutical agents in a given drug class. The Company must record the Condition Set # that applies to a given UF-VARR quote in the appropriate blank on Table 1, Uniform Formulary Refund Quote.

The refund quoted will apply to the resulting UF-VARR if the quoted pharmaceutical agent is selected for inclusion on the UF in no worse than the formulary (Tier 2) cost share. The refund quoted is not contingent on the quoted pharmaceutical agent being selected for inclusion on the BCF or ECF.

| NDC | Drug Name | Strength | Dosage Form | Package Size |  |
|-----|-----------|----------|-------------|--------------|--|
|     |           |          |             |              |  |

# DoD P&T Class: HEPATITIS C AGENTS Subclass: DIRECT ACTING AGENTS Class Note(s): Grandfathering applies to this class/subclass.

Step Therapy Addendum: Step therapy, a prior authorization process, would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be

excluded from the prior authorization process. Step therapy applies to Hepatitis C Genotype 1 ONLY Total Offered Retail Standard Refund per Most recent Current Additional Refund per **FCP** Refund per **Annual Non-**Annual FCP **Package Federal Average Federal FCP Package** Size One of (X) Manufacturer's Ceiling **Package CHANGES** Size Number of Price\* (NFAMP) Price\* (FCP) Size Condition Set # Category\*\* **CHANGES ANNUALLY** brand per FCP Package per FCP Percentage **ANNUALLY** (((NFAMP agents is Static Size. Package ((NFAMP -- FCP CHANGES Size. **NFAMP** FCP )/NFAMP) **ANNUALLY CHANGES** \*(Y%) )/NFAMP) \*100 = X%) **ANNUALLY** (\$) (%) \*100 = X% + (NFAMP (\$) \*(Y%)) = (%) Total% (%) Uniform **Formulary** & Tier 2 153HCDIG1T2BS1X 1 \$ \$ % % % Before Step Therapy Uniform **Formulary** & Tier 2 153HCDIG1T2BS2X 2 \$ \$ % % % Before Step Therapy

| 153HCDIG0T2NS1M | Uniform<br>Formulary<br>& Tier 2 No<br>Step<br>Therapy                            | 1 or more | \$<br>\$ | % | % | % |
|-----------------|---|-----------|----------|---|---|---|
|                 |   |           |          |   |   |   |
| 153HCDIG1T2AS1M | Uniform Formulary & Tier 2 After Step with preferred agent(s) Before Step Therapy | 1 or more | \$<br>\$ | % | % | % |

<sup>\*\*</sup> Only one price per category may be submitted.